PMID: 9449261Feb 4, 1998Paper

Host mutations (miaA and rpsL) reduce tetracycline resistance mediated by Tet(O) and Tet(M)

Antimicrobial Agents and Chemotherapy
D E TaylorM Bekkering

Abstract

The effects of mutations in host genes on tetracycline resistance mediated by the Tet(O) and Tet(M) ribosomal protection proteins, which originated in Campylobacter spp. and Streptococcus spp., respectively, were investigated by using mutants of Salmonella typhimurium and Escherichia coli. The miaA, miaB, and miaAB double mutants of S. typhimurium specify enzymes for tRNA modification at the adenosine at position 37, adjacent to the anticodon in tRNA. In S. typhimurium, this involves biosynthesis of N6-(4-hydroxyisopentenyl)-2-methylthio-adenosine (ms2io6A). The miaA mutation reduced the level of tetracycline resistance mediated by both Tet(O) and Tet(M), but the latter showed a greater effect, which was ascribed to the isopentenyl (i6) group or to a combination of the methylthioadenosine (ms2) and i6 groups but not to the ms2 group alone (specified by miaB). In addition, mutations in E. coli rpsL genes, generating both streptomycin-resistant and streptomycin-dependent strains, were also shown to reduce the level of tetracycline resistance mediated by Tet(O) and Tet(M). The single-site amino acid substitutions present in the rpsL mutations were pleiotropic in their effects on tetracycline MICs. These mutants affect translationa...Continue Reading

References

Nov 24, 1979·Nucleic Acids Research·H C Birnboim, J Doly
Apr 20, 1992·Journal of Molecular Biology·N BilginM Ehrenberg
Oct 1, 1991·Antimicrobial Agents and Chemotherapy·Y Wang, D E Taylor
Jun 1, 1991·Journal of Bacteriology·I TubulekasD Hughes
Dec 1, 1988·Antimicrobial Agents and Chemotherapy·R ZilhaoP Courvalin
Feb 1, 1986·Molecular & General Genetics : MGG·I DiazC G Kurland
Apr 9, 1974·Molecular & General Genetics : MGG·F J Sánchez-Anzaldo, F Bastarrachea
Jan 1, 1984·Molecular & General Genetics : MGG·K BohmanC G Kurland
Mar 1, 1982·Journal of Bacteriology·V BurdettS Rajagopalan
Jan 1, 1995·Progress in Nucleic Acid Research and Molecular Biology·G R Björk
Jan 1, 1994·Biochimie·B C PerssonG R Björk
Dec 1, 1994·European Journal of Biochemistry·R Karimi, M Ehrenberg
Jan 1, 1996·Progress in Nucleic Acid Research and Molecular Biology·J Czworkowski, P B Moore
Jan 1, 1996·Antimicrobial Agents and Chemotherapy·D E Taylor, A Chau
Dec 1, 1996·Antimicrobial Agents and Chemotherapy·C A WiddowsonD Hanslo

❮ Previous
Next ❯

Citations

May 31, 2001·Microbiology and Molecular Biology Reviews : MMBR·I Chopra, M Roberts
Oct 22, 2005·FEMS Microbiology Letters·Martin Iain BahlSøren J Sørensen
Sep 22, 2010·Journal of the American Chemical Society·Petr ValentaPatrick J Walsh

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.